RE:RE:RE:RE:When you compareLithLover wrote: So you discount Stagezero's Covid revenue but not Exas both of which had y/y increase over 20%. Stage diversifies and now has over $1 million per quarter from Care and it's growing but hey why not disregard that too. Revenue is revenue.
Can't fix stupid here.
The market cap will increase with revenues over the next few quarters. They don't report Q1 until May 16 so not having this arguement daily until than. I'm comfortable knowing revenues are increasing.
If you can't see the company has taken strides to grow multiple revenue streams and that the market cap at only 3x revenues is way undervalued than you truly are just bashing for the sake of bashing. Yes they have a loss as do Billion dollar companies. This is about revenue growth and despite the roll out taking over a year revenues are increasing with AVRT, TREAT and ARISTOTLE in the US, Canada, UK and Europe. All adding to revenue growth and the bottom line.
So wait on the sidelines or buy and hold but the SP will be increasing with more revenues.
Your lack of business acumen is telling.
You think that? The share price will increase from $0,02 LMAO
CAN'T FIX STUPID HERE